BullFrog AI seeks to leverage its revolutionary bfLEAP platform to transform the field of precision medicine. Our mission is to apply predictive analytics to all stages of drug development to improve the lives of every patient.
BullFrog AI consists of an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors determined to revolutionize drug development. And through our partnership with one of the most prestigious research institutions in the world, Johns Hopkins, we are at the forefront of AI technology development.
Founder & former CEO, Next Healthcare Inc.
Co-founder, MaxCyte Inc. – Nasdaq (MXCT) – $1.5B market cap
Global Director, Cell Therapy – ThermoFisher Scientific
B.S. Electrical Engineering, Rutgers University
M.S. Biomedical Engineering, Rensselaer Polytechnic Institute
MBA, The Johns Hopkins University
Using a multivariate analytical approach, we seek to profile the right patient for the right drug at the right dose.
We can also apply our technology in the discovery and pre-clinical stages of drug development, to improve our partners’ likelihood of success in development and clinical trials.
AI can be used to identify predictors of drug response that may not be hypothesized by scientists and clinicians.”
I envision that AI, in combination with other cutting edge technologies like engineering biology, will accelerate the development of precision cancer treatments.”